Drug Profile
Research programme: NF-kappa B inhibitors - Profectus Biosciences
Alternative Names: PBS-1086Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Profectus Biosciences
- Class Small molecules
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in USA